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Abstract 
The UK Office for National Statistics (ONS) publish a regular infection survey 
that reports data on positive RT-PCR test results for SARS-COV-2 virus. This 
survey reports that a large proportion of positive test results may be based on the 
detection of a single target gene rather than on two or more target genes as 
required in the manufacturer instructions for use, and by the WHO in their 
emergency use assessment. Without diagnostic validation, for both the original 
virus and any variants, it is not clear what can be concluded from a positive test 
resulting from a single target gene call, especially if there was no confirmatory 
testing. Given this, many of the reported positive results may be inconclusive, 
negative or from people who suffered past infection for SARS-COV-2. 
 
Background 
The efficacy of mass population testing for SARS-COV-2 virus is critically dependent on the 
reliability of the test applied, whether it be a RT-PCR or lateral flow test. Given that many RT-
PCR tests do not actually target all the genes necessary to reliably detect SARS-COV-2, the 
results of mass testing using RT-PCR need to be revisited and reanalysed. 
The ONS publish a regular infection survey [1], [20] that includes data from two UK lighthouse 
laboratories, based in Glasgow and Milton Keynes, where both use the same RT-PCR test kit, 
to detect the SARS-COV-2 virus. This survey includes data on the cycle threshold (Ct) used to 
detect positive samples, the percentage of positive test results arising from using RT-PCR, and 
the combinations of the SARS-COV-2 virus target genes tested that gave rise to positives 
between 21 September 2020 and 1 March 2021 across the whole of the UK. 
The kit used by the Glasgow and Milton Keynes lighthouse laboratories is the ThermoFisher 
TaqPath RT-PCR1 which tests for the presence of three target genes from SARS-COV-22 [11]. 
Despite Corman et al [2] originating the use of PCR testing for SARS-COV-2 genes3 there is 
no agreed international standard for SARS-COV-2 testing. Instead, the World Health 
Organisation (WHO) leaves it up to the manufacturer to determine what genes to use and 
instructs end users to adhere to the manufacturer instructions for use (IFU). As a result of this 
 
1 The full name for ThermoFisher TaqPath kit is TaqPath COVID‑19 CE‑IVD RT‑PCR. 
2 N, S and ORF1ab genes 
3 Corman et al recommended the E, N and RdRp genes 
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we now have an opaque plethora of commercially available testing kits, that can be applied 
using a variety of test criteria. Other UK laboratories use different testing kit, and test for 
different genes. 
The WHO’s emergency use assessment (EUA) for the ThermoFisher TaqPath kit [3] includes 
the instruction manual and contained therein is an interpretation algorithm describing an 
unequivocal requirement that two or more target genes be detected before a positive result can 
be declared. This is shown in Table 1. The latest revision of ThermoFisher’s instruction manual 
contains the same algorithm [21]. 
 
Table 1: Screenshot of results interpretation ThermoFisher TaqPath IFU on page 60 of [3] (their Table 6) 
The WHO have been so concerned about correct use of RT-PCR kit that on 20 January 2021 
they issued a notice for PCR users imploring them to review manufacturer IFUs carefully and 
adhere to them fully [4]. 
Increasing proportion of single gene target “calls” 
The ONS’s report [1] lists SARS-COV-2 positive results for valid two and three target gene 
combinations4 and does the same in [20], for samples processed by the Glasgow and Milton 
Keynes lighthouse laboratories. However, it also lists single gene detections as positive results5 
(See tables 6a and 6b). This use of single gene “calls” suggests that these lighthouse 
laboratories may have breached WHO emergency use assessment (EUA) and potentially 
violated the manufacturer instructions for use (IFU). According to the WHO, such single gene 
calls should be classified as inconclusive test results. However, Section 10 of this ONS Covid-
19 Infection survey report [5] on the 8 January 2021 stated that one gene is sufficient for a 
positive result (emphasis mine): 
“Swabs are tested for three genes present in the coronavirus: N protein, S protein and 
ORF1ab. Each swab can have any one, any two or all three genes detected. Positives 
are those where one or more of these genes is detected in the swab …..” 
Over the period reported the maximum weekly percentage of positives on a single gene is 38% 
for the whole of the UK for the week of 1 February. The overall UK average was 23%. The 
 
4 N+S+ORF, ORF+S, N+S and N+ORF gene combinations 
5 N alone, ORF alone (note that the S gene is included in the ONS analysis but is never counted as a positive if it is detected in isolation) 
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maximum percentage reported is 65%, in East England in the week beginning 5 October. In 
Wales it was 50%, in Northern Ireland it is 55% and in Scotland it was 56%. The full data 
including averages and maxima/minima are given in Table 2. 
Figures 1 and 2 show the percentage of weekly single gene positives across the UK nations and 
English regions. There has been a significant increase in the percentage of single gene positives 
since the end of 2020, rising from January, and here the rise is steady across all English regions 
and UK nations. 
 
Table 2: Percentage of weekly single gene positives from 21 September 2020 to 1 March 2021, including 

























































































21 September 2020 17 17 0 33 0 6 14 22 40 9 18 9 40 58
28 September 2020 13 13 0 0 0 4 13 10 26 9 25 13 24 16
5 October 2020 19 19 14 6 16 8 9 9 11 16 65 32 58 34
12 October 2020 15 15 16 14 21 16 14 13 16 15 19 19 19 18
19 October 2020 19 19 34 24 13 28 12 17 25 18 28 28 19 21
26 October 2020 13 15 4 25 5 11 11 12 17 14 20 16 21 15
2 November 2020 16 16 18 10 23 18 13 13 17 14 23 25 17 13
9 November 2020 21 20 25 40 29 14 19 19 20 25 23 18 21 24
16 November 2020 17 17 10 6 22 11 25 20 18 19 13 13 13 16
23 November 2020 24 23 44 7 34 30 28 26 35 21 22 9 16 22
30 November 2020 29 29 25 18 32 46 40 49 28 24 18 17 29 22
7 December 2020 27 27 21 13 30 47 38 44 25 37 10 13 29 42
14 December 2020 15 15 1 7 29 20 20 23 19 24 10 9 11 31
21 December 2020 13 13 12 0 32 15 25 16 14 18 12 7 9 40
28 December 2020 20 20 19 10 31 29 22 29 19 16 17 15 16 36
4 January 2021 17 16 22 16 35 9 18 22 19 9 11 16 16 22
11 January 2021 29 28 48 23 38 28 29 43 31 18 36 25 28 25
18 January 2021 33 32 42 38 48 41 25 34 32 30 32 31 32 42
25 January 2021 35 33 50 42 35 25 28 28 34 31 37 36 38 39
1 February 2021 38 39 39 49 30 22 28 27 31 30 49 43 47 37
8 February 2021 35 36 16 55 34 32 31 28 35 28 41 40 38 43
15 February 2021 33 33 38 24 39 32 29 33 26 40 32 37 31 26
22 February 2021 31 32 33 9 36 15 30 30 38 35 31 34 32 25
1 March 2021 33 30 44 36 56 50 15 23 38 29 37 40 32 21
Average 23 23 24 21 28 23 22 25 26 22 26 23 27 29
Min 13 13 0 0 0 4 9 9 11 9 10 7 9 13




Figure 1: Percentage of weekly single gene positives from 21 September 2020 to 25 January 2021 (UK 
nations) 
 
Figure 2: Percentage of weekly single gene positives from 21 September 2020 to 25 January 2021 (English 
regions) 
Professor Alan McNally, Director of the University of Birmingham Turnkey laboratory, who 
helped set up the Milton Keynes lighthouse laboratory, contradicted what was stated in the 
ONS report in a Guardian newspaper article about the new variant. He reported that all 
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requiring two-or-more genes for positive detection [6] (this policy is also documented in [22], 
which defines the standard operating procedure reported in [7]). 
In correspondence with Mr Nicholas Lewis about single gene testing, in February 2021, the 
ONS confirmed that they do indeed call single gene targets as positives in their Covid-19 
Infection Survey and also confirmed that the samples are processed by UK lighthouse 
laboratories [8], [9]. 
As early as April 2020, the UK lighthouse laboratories were testing for single genes and 
discounted the S gene as early as mid-May [10], months before the discovery of the new variant 
B1.1.7 (emphasis mine): 
“Swabs were analysed at the UK’s national Lighthouse Laboratories at Milton Keynes 
(National Biocentre) (from 26 April) and Glasgow (from 16 August) …., with swabs 
from specific regions sent consistently to one laboratory. RT-PCR for three SARS-
CoV-2 genes (N protein, S protein and ORF1ab) ..... Samples are called positive in the 
presence of at least single N gene and/or ORF1ab but may be accompanied with S gene 
(1, 2 or 3 gene positives). S gene is not considered a reliable single gene positive (as of 
mid-May 2020).” 
Indeed, in Table 1 of [10] 18% of tests were positive on one gene only and it was concluded, 
in Table 2 of [10] that, for people with single gene positives, when Ct > 34, none had symptoms 
and for people with Ct < 34 only 33% had symptoms. 
Furthermore in a Public Health England report on variants [11], published January 8th 2021, it 
states the goal of using one gene was explicitly to approximate the growth of the new B1.1.7 
variant (emphasis mine): 
“There has recently been an increase in the percentage of positive cases where only the 
ORF1ab- and N-genes were found and a decrease in the percentage of cases with all 
three genes. We can use this information to approximate the growth of the new 
variant.” 
Quality control and cross reactivity 
Quality control problems have already been reported in UK laboratories [12, 13, 14] and 
concerns have been expressed about the potential for false positives arising consequently. 
Recent suspicion focused on problems potentially caused by exceeding acceptable Ct 
thresholds, suggesting no, or past, infection. However, this new ONS data shows there may be 
an additional potentially dominant source of false positives, at least within the period covered 
by the ONS report, if not from April 2020. 
Concerns about testing in commercial laboratories were documented by the ONS as early as 
May 2020 [15], when the REACT study discovered that circa 40% of positive tests from 
commercial laboratories were in fact false positives. A similar false positive rate (44%) was 
reported in Australia [16] in April 2020.  More recently Mr Nicholas Lewis claims that, despite 
very low false positive rates (0.033%) from testing done by non-commercial and academic 
laboratories, there may be reason to suspect the operational false positive rates from lighthouse 
laboratories may be worse than these by some orders of magnitude [17]. 
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Obviously, there is a higher risk of encountering false positives when testing for single genes 
alone, because of the possibility of cross-reactivity with other human coronaviruses (HCOVs) 
and prevalent bacteria or reagent contamination. The potential for cross reactivity when testing 
for SARS-COV-2 has already been confirmed by the German Instand laboratory report from 
April 2020 [18] (note that Prof. Drosten, co-author of Corman et al [2] is a cooperating partner 
listed in this report). The report describes the systematic blind testing of positive and negative 
samples anonymously sent to 463 laboratories from 36 countries and evaluated for the presence 
of a variety of genes associated with SARS-COV-26. They reported significant cross reactivity 
and resultant false positives for OC43, and HCoV 229E (a common cold virus) as well as for 
SARS-COV-2 negative samples, not containing any competing pathogen. Likewise, 70 Dutch 
laboratories were surveyed in November 2020, by the National Institute for Public Health and 
the Environment [19], with 76 diagnostic workflows reported as using only one target gene to 
diagnose the presence of SARS-COV-2 (46% of all workflows). 
Conclusions 
Without diagnostic validation, for both the original virus and any variants, it is not clear what 
can be concluded from a positive test resulting from a single target gene call, especially if there 
was no confirmatory testing. Many of the reported positive results may be inconclusive, 
negative or from people who suffered past infection for SARS-COV-2. Even with diagnostic 
validation of the single target gene call, the UK lighthouse laboratories appear not to be in strict 
conformance with the WHO emergency use assessment and the manufacturer instructions for 
use. Given this it is clear the ONS and the UK lighthouse laboratories needs to publicly clarify 
their use of, and justify the reasons for, deviating from these standards. 
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